Navigation Links
FDA Approves Combination Contraceptive Containing a Folate

SILVER SPRING, Md., Sept. 24 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Beyaz tablets, an estrogen/progestin combined oral contraceptive that also contains a folate (levomefolate calcium 0.451 mg).



Levomefolate calcium is a metabolite of folic acid, a water-soluble B-vitamin that helps produce and maintain new cells in the body. A known association of low folate levels and neural tube defects (e.g., spina bifida) has resulted in recommendations that women of childbearing age supplement their diet with folate.

Beyaz is based on the approved product YAZ, which contains the same doses of estrogen and progestin, and is approved for:

  • Prevention of pregnancy
  • Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive for contraception and
  • Treatment of moderate acne vulgaris in women at least 14 years of age, only if the patient desires an oral contraceptive for birth control.

In addition to the approved YAZ indications, Beyaz also is approved for the secondary indication in women who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.

The primary efficacy study for Beyaz was a multicenter, double-blind, randomized, controlled U.S. trial in 379 healthy women age 18 to 40 who were treated with Beyaz or YAZ alone for up to 24 weeks. Beyaz was found to increase folate levels in women. In a German study of Beyaz, folate levels remained elevated for several weeks following discontinuation of Beyaz.  Safety and efficacy data for contraception, PMDD, and acne indications were obtained from previous YAZ clinical trials.

The most common side effects reported by users of combined oral contraceptives are irregular uterine bleeding, nausea, breast tenderness, and headaches. Other serious side effects include vascular events (blood clots) and liver disease.  Women over age 35 who smoke should not use this product as cigarette smoking increases further the risk of serious cardiovascular events.  The common adverse events for Beyaz are expected to be the same as those for YAZ.  There were no findings from the clinical trials with Beyaz to suggest a change in the overall safety profile compared to that of YAZ.

Beyaz is manufactured by Bayer HealthCare Pharmaceuticals Inc., the U.S.-based business arm of Bayer HealthCare LLC, a subsidiary of Bayer AG.

Approved Drugs: Questions and Answers

Contact: Elaine Gansz Bobo, 301-796-7567,

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
2. FDA Approves NDA That Includes Psychiatric Data Collected by Centralized Raters
3. FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
4. FDA Approves Pediatric Use of Chemical Poisoning Treatment
5. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
6. FDA Approves Vaccines for the 2010-2011 Influenza Season
7. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
8. FDA Approves Sagent Pharmaceuticals Heparin Sodium Injection, USP
9. U.S. FDA Approves Improved Performance of Riverain Medicals OnGuard Chest X-ray Computer-Aided Detection Technology
10. FDA Approves New Injectable Osteoporosis Treatment for Postmenopausal Women
11. FDA Approves New Treatment for Late-Onset Pompe Disease
Post Your Comments:
(Date:12/1/2015)... , Dec. 01, 2015 ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ... "Veterinary Equipment and Disposables Market by product, ... report to their offering. --> Research ...
(Date:12/1/2015)... 2015 CytRx Corporation (NASDAQ: CYTR ), ... today announced that it has reached its enrollment target ... 3 clinical trial of aldoxorubicin in patients with previously ... be completed in Q1 2016. The Phase 3 trial is ... Protocol Assessment from the FDA at 79 sites in ...
(Date:12/1/2015)... , Dec. 1, 2015  InCarda Therapeutics, Inc. (InCarda), ... commercialization of therapies for cardiovascular conditions via the inhalation ... business in Australia . InCarda is ... Australia in the first half ... and medical centers in Adelaide ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Physicians’ Education Resource®, LLC (PER®) ... announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will be held ... treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with powerful new ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and ... believe that with innovative technologies and under the right circumstances, these practices can ... benefit of a dual-approach to his or her therapeutic sessions, as well as ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
Breaking Medicine News(10 mins):